Batu Biologics Achieves Goal in Successful Crowdfunding Campaign

Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine August 18th, 2014 Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform. Batu Biologics launched the crowdfunding campaign in June 2014 to fund the completion …